The 20 Best Muscle Invasive Bladder Cancer Doctors Near Me

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Mehmet Bilen is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 18 years. Dr. Bilen is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Bilen is board certified in American Board Of Internal Medicine, 2016.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Kates is board certified in American Board Of Urology.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Nephrectomy. Dr. Hoffman is board certified in American Board Of Internal Medicine.

Bradley Carthon is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 21 years. Dr. Carthon is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy. Dr. Carthon is board certified in American Board Of Internal Medicine, 2011.

Omer Kucuk is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 51 years. Dr. Kucuk is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Prostatectomy. Dr. Kucuk is board certified in American Board Of Internal Medicine, 1989.

Morgan Roupret practices practicing medicine in Paris, France. Mr. Roupret is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Bladder Cancer, Nephrectomy, and Cystectomy.

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.

Ajjai Alva is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Alva is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Daniel Castellano practices practicing medicine in Madrid, Spain. Mr. Castellano is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, Cystectomy, and Orchiectomy.

Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are. In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors. After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network. A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time. Dr. Koshkin is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Non-Muscle Invasive Bladder Cancer, and Lymphadenectomy. Dr. Koshkin is board certified in American Board Of Internal Medicine, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. Dr. Koshkin is currently accepting new patients.

Yair Lotan is a Urologist practicing medicine in Dallas, Texas. Dr. Lotan is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 44 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Marco Moschini practices practicing medicine in Barcelona, Spain. Mr. Moschini is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Prostatectomy.

Toni Choueiri is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choueiri is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy.

Sumanta Pal is an Oncologist practicing medicine in Irvine, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Ashish Kamat is a Urologist practicing medicine in Cary, North Carolina. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Neal Shore is a Urologist practicing medicine in Myrtle Beach, South Carolina. Dr. Shore is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Shore is currently accepting new patients.

Guru Sonpavde is an Oncologist practicing medicine in Orlando, Florida. Dr. Sonpavde is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Bradley Mcgregor is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcgregor is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Muscle Invasive Bladder Cancer, Tissue Biopsy, and Nephrectomy.